| |
Expression Analysis Relocates to Larger Laboratory Facility while Expanding its Genomic Services and Staff
Durham, N.C. (February 21, 2007)— Expression Analysis, Inc., the industry’s leading provider of Affymetrix GeneChip® brand microarray services for clinical trials, announced today that it has relocated its GLP-compliant laboratory to a larger facility in Durham, NC. After doubling its revenue in fiscal 2006, the company has increased its staff and expanded the service offerings to meet the needs of its growing client base.
The new facility, located on 4324 South Alston Avenue in Durham, NC, provides a three-fold increase in the amount of laboratory space. Dr. Thomas Goralski, Vice President of Laboratory Operations said, “Last year we tripled our capacity for Affymetrix GeneChip testing and dramatically increased both our gene expression and genotyping services. We quickly out grew our current facility and look forward to the new site.”
The larger facility also enables the installation of new equipment required for higher throughput Affymetrix testing as well as complementary services using other platforms. Mr. Steve McPhail, CEO of Expression Analysis said, “Our clients have requested a variety of solutions for their gene expression and genotyping studies. We are working to meet their needs by introducing new approaches for testing RNA and DNA specimens from formalin-fixed, paraffin-embedded tissues on the Affymetrix platform and by initiating genomic services using Illumina, Luminex and Applied Biosystems’ TaqMan® technology platforms.”
In the last six months, Expression Analysis doubled its laboratory and informatics personnel. The company also created a dedicated marketing team and added two experienced US sales representatives for pharmaceutical and biotechnology accounts. Ms. Molly Gleizes was previously with two genomic bioinformatics companies. She resides outside Seattle, WA and brings over six years of field experience in genomic services. She will cover clients in the Western U.S. region. Ms. Kellie Yarnell has eight years experience with genomics & molecular biology products as well as instrument sales. She lives in New York City and will be responsible for clients in the Eastern U.S. region. Mr. Jim Parina, Senior Director of Sales & Marketing said, “We are very excited about the addition of these two seasoned sales specialists to our team. Molly and Kellie both bring, to our rapidly growing company, the experience, skills and market knowledge we require in this period of explosive growth.”
About Expression Analysis, Inc.
Expression Analysis, Inc. (http://www.expressionanalysis.com) is the industry’s leading provider of microarray-based genomic services for clinical trials. Specializing in gene expression and genotyping assays on Affymetrix GeneChips®, the company became the first service provider to offer GLP-compliant microarray testing in the world. Expression Analysis provides comprehensive genomics testing offering high throughput, high quality and cost-effective results in a regulatory-compliant environment.
|
|
